The B-cell lymphoma 2 (Bcl-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member Bcl-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukaemia.
Servier collaborates with Novartis for the clinical development of S55746. The candidate is currently being tested in multiple phase 1 studies in patients with chronic lymphocytic leukaemia (CLL), B-Cell non-Hodgkin lymphoma (NHL), multiple myeloma (MM), follicular lymphoma (FL) and mantle cell lymphoma (MCL).
Vernalis Research is entitled to receive development milestones and royalties on net sales.